Anbio Biotechnology
NNNN Nasdaq In Vitro & In Vivo Diagnostic Substances Financials FY2022–FY2025
What Anbio Biotechnology does
No business description yet.
- Legal name
- Anbio Biotechnology
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 20-F · Apr 7, 2026
- Accession · CIK
- 0001185185-26-001294
0001982708
Revenue and margins
Anbio Biotechnology had $8.6M of revenue in fiscal 2025, up 5.6% on the year before.
Net income and earnings per share
From fiscal 2022 to 2025, diluted EPS grew −98.9% a year. Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was — in fiscal 2025, — of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Anbio Biotechnology returned — to shareholders in fiscal 2025. The diluted share count rose 3.3%.
Balance sheet
Cash, debt and the ratios that show how comfortably Anbio Biotechnology can carry it.
| Fiscal year end | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | $7.1M | $9.7M | $11.8M | $11.9M |
| Interest coverage | 1,274.5x | — | — | — |
| Current ratio | — | 15.9x | 10.7x | 344.5x |
| Quick ratio | — | 15.9x | 10.7x | 344.5x |
| Total assets | — | $15.8M | $18.9M | $30.2M |
| Total liabilities | — | $1.0M | $1.7M | $0.1M |
| Shareholders' equity | $12.5M | $14.8M | $17.2M | $30.2M |
| Net debt (− = net cash) | — | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Net income is positive | ✓ | ✓ | ✓ | ✓ |
| Cash from operations is positive | ✓ | ✓ | ✓ | ✕ |
| Return on assets rose | — | — | ✕ | ✓ |
| Cash from operations exceeds net income | ✕ | ✕ | ✕ | ✕ |
| Debt fell relative to assets | — | — | — | — |
| Current ratio rose | — | — | ✕ | ✓ |
| Share count didn't rise | — | — | ✕ | ✕ |
| Gross margin rose | — | ✕ | ✓ | ✓ |
| Revenue rose relative to assets | — | — | ✓ | ✕ |
| F-score | — / 3 | — / 4 | 4 / 8 | 4 / 8 |
| Accruals ratio | — | 8.6% | 1.7% | 53.5% |
| Altman Z'' | — | 25.67 | 19.93 | 370.99 |
4 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $23.5M | $6.7M | $8.2M | $8.6M |
| Gross profit | $12.6M | $3.4M | $5.9M | $7.5M |
| Research and development | $0.2M | $0.1M | $0.5M | $0.2M |
| Operating income | $10.2M | $2.0M | $2.0M | $5.8M |
| Interest expense | $0.0M | — | — | — |
| Pretax income | $10.0M | $2.3M | $2.4M | $6.4M |
| Income tax | — | $0.0M | $0.0M | $0.0M |
| Net income | $10.0M | $2.3M | $2.4M | $6.4M |
| Diluted EPS | $100,112.00 | $0.11 | $0.06 | $0.15 |
| Diluted shares | — | 0.02B | 0.04B | 0.04B |
| Cash flow | ||||
| Cash from operations | $4.4M | $0.9M | $2.1M | −$6.7M |
| Balance sheet | ||||
| Cash and short-term investments | $7.1M | $9.7M | $11.8M | $11.9M |
| Current assets | — | $15.7M | $18.5M | $30.2M |
| Current liabilities | — | $1.0M | $1.7M | $0.1M |
| Total assets | — | $15.8M | $18.9M | $30.2M |
| Total liabilities | — | $1.0M | $1.7M | $0.1M |
| Shareholders' equity | $12.5M | $14.8M | $17.2M | $30.2M |
| Margins | ||||
| Gross margin | 53.4% | 50.1% | 71.9% | 87.2% |
| Operating margin | 43.3% | 29.2% | 24.4% | 66.7% |
| Net margin | 42.5% | 33.6% | 29.0% | 74.1% |
| Returns | ||||
| Return on capital employed | — | 13.2% | 11.6% | 19.1% |
| Return on equity | 79.8% | 16.5% | 14.8% | 27.0% |
| Return on assets | — | 14.3% | 13.7% | 26.0% |
| Return on tangible equity | 79.8% | 15.2% | 13.8% | 21.2% |
| Growth | ||||
| Revenue growth | — | −71.5% | 21.9% | 5.6% |
| Net income growth | — | −77.5% | 5.3% | 169.9% |
| EPS growth | — | −100.0% | −46.7% | 162.5% |
| Share count change | — | — | 97.3% | 3.3% |
| Financial health | ||||
| Interest coverage | 1,274.5x | — | — | — |
| Current ratio | — | 15.9x | 10.7x | 344.5x |
| Quick ratio | — | 15.9x | 10.7x | 344.5x |
| Quality scores | ||||
| Piotroski F-score | — | — | 4.0 | 4.0 |
| Altman Z'' | — | 25.7 | 19.9 | 371.0 |
| Accruals ratio | — | 8.6% | 1.7% | 53.5% |
Source: SEC EDGAR XBRL filings (CIK 0001982708). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.